Taste alterations in breast and gynaecological cancer patients receiving chemotherapy: Prevalence, course of severity, and quality of life correlates

References

• Hong JH, Omur-Ozbek P, Stanek BT, Dietrich AM, Duncan SE, Lee YW, . Taste and odor abnormalities in cancer patients. J Support Oncol 2009;7:58–65.
   PubMedGoogle Scholar
• Ravasco P, Monteiro-Grillo I, Marques Vidal P, Camilo Maria E. Impact of nutrition on outcome: A prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck 2005;27:659–68.
   PubMed Web of Science ®Google Scholar
• Comeau TB, Epstein JB, Migas C. Taste and smell dysfunction in patients receiving chemotherapy: A review of current knowledge. Support Care Cancer 2001;9:575–80.
   PubMed Web of Science ®Google Scholar
• Epstein JB, Robertson M, Emerton S, Phillips N, Stevenson-Moore P. Quality of life and oral function in patients treated with radiation therapy for head and neck cancer. Head Neck 2001;23:389–98.
   PubMed Web of Science ®Google Scholar
• Laky B, Janda M, Kondalsamy-Chennakesavan S, Cleghorn G, Obermair A. Pretreatment malnutrition and quality of life – association with prolonged length of hospital stay among patients with gynecological cancer: A cohort study. BMC Cancer 2010;10:232.
   PubMed Web of Science ®Google Scholar
• Jensen SB, Mouridsen HT, Bergmann OJ, Reibel J, Brunner N, Nauntofte B. Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;106:217–26.
   PubMed Web of Science ®Google Scholar
• Lindley C, McCune JS, Thomason TE, Lauder D, Sauls A, Adkins S, . Perception of chemotherapy side effects cancer versus noncancer patients. Cancer Pract 1999;7:59–65.
   PubMedGoogle Scholar
• Bernhardson BM, Tishelman C, Rutqvist LE. Self-reported taste and smell changes during cancer chemotherapy. Support Care Cancer 2008;16:275–83.
   PubMed Web of Science ®Google Scholar
• Wickham RS, Rehwaldt M, Kefer C, Shott S, Abbas K, Glynn-Tucker E, . Taste changes experienced by patients receiving chemotherapy. Oncol Nurs Forum 1999;24:697–706.
   Google Scholar
• Rehwaldt M, Wickham R, Purl S, Tariman J, Blendowski C, Shott S, . Self-care strategies to cope with taste changes after chemotherapy. Oncol Nurs Forum 2009;36:E47–56.
   PubMedGoogle Scholar
• Brewin TB. Can a tumour cause the same appetite perversion or taste change as a pregnancy? Lancet Oncol 1980;25:907–8.
   Google Scholar
• DeWys WD. Changes in taste sensation and feeding behaviour in cancer patients: A review. J Hum Nutr 1978;32:447–53.
   PubMedGoogle Scholar
• Ripamonti C, Zecca E, Brunelli C, Fulfaro F, Villa S, Balzarini A, . A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation. Cancer 1998;82:1938–45.
   PubMed Web of Science ®Google Scholar
• Zabernigg A, Gamper EM, Giesinger JM, Rumpold G, Kemmler G, Gattringer K, . Taste alterations in cancer patients receiving chemotherapy: A neglected side effect? Oncologist 2010;15:913–20.
   PubMed Web of Science ®Google Scholar
• Holzner B, Rumpold G. Computer-based Health Evaluation System (CHES) Version 3.0. In. 3.0 ed. Innsbruck: Evaluation Software Development; 2005.
   Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, . The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–76.
   PubMed Web of Science ®Google Scholar
• EORTC QLG Item Bank [Internet]. Brussels: European Organisation for Research and Treatment of Cancer. [cited 2010 Jul]. Available from: http://groups.eortc.be/qol/glossary.htm
   Google Scholar
• Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A. Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006;100:273–84.
   PubMed Web of Science ®Google Scholar
• Johnsen AT, Tholstrup D, Petersen MA, Pedersen L, Groenvold M. Health related quality of life in a nationally representative sample of haematological patients. Eur J Haematol 2009;83:139–48.
   PubMed Web of Science ®Google Scholar
• Oberguggenberger A, Hubalek M, Sztankay M, Meraner V, Beer B, Oberacher H, . Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs). Breast Cancer Res Treat 2011;128:553–61.
   PubMedGoogle Scholar
• Lorusso D, Ferrandina G, Fruscella E, Marini L, Adamo V, Scambia G. Gemcitabine in epithelial ovarian cancer treatment: Current role and future perspectives. Int J Gynecol Cancer 2005;15:1002–13.
   PubMedGoogle Scholar
• Guarneri V, Piacentini F, Barbieri E, Conte PF. Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol 2010;117:152–8.
   PubMed Web of Science ®Google Scholar
• Covens A, Carey MS, Bryson P, Verma s, Fung Kee Fung M, Johnston M. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol 2002;85:71–80.
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BH, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, . Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194–200.
   PubMed Web of Science ®Google Scholar
• Dodde WIW, Maring JG, Hendriks G, Wachters FM, Groen HJM, de Vries EGE, . Determination of epirubicin and its metabolite epirubicinol in saliva and plasma by HPLC. Ther Drug Monit 2003;25:433–40.
   PubMed Web of Science ®Google Scholar
• Gluck S. Adjuvant chemotherapy for early breast cancer: Optimal use of epirubicin. Oncologist 2005;10:780–91.
   PubMed Web of Science ®Google Scholar
• Pellegrini F, Budman DR. Review: Tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest 2005;23:264–73.
   PubMed Web of Science ®Google Scholar
• Look MP, Musch E. Lipid peroxides in the polychemotherapy of cancer patients. Chemotherapy 1994;40:8–15.
   PubMed Web of Science ®Google Scholar
• Kennedy BJ. 5-fluorouracil toxicity: Old or new? Cancer 1999;86:1099–100.
   PubMedGoogle Scholar
• De Placido S, Lopez M, Carlomagno C, Paoletti G, Palazzo S, Manzione L, . Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: The IGCS-COL multicentre, randomised, phase III study. Br J Cancer 2005;93:896–904.
   PubMedGoogle Scholar
• Sanchez-Lara K, Sosa-Sanchez R, Green-Renner D, Rodriguez C, Laviano A, Motola-Kuba D, . Influence of taste disorders on dietary behaviors in cancer patients under chemotherapy. Nutr J 2010;9:15.
   PubMed Web of Science ®Google Scholar
• Mattes RD, Arnold C, Boraas M. Learned food aversions among cancer chemotherapy patients. Incidence, nature, and clinical implications. Cancer 1987;60:2576–80.
   Google Scholar
• Lees J. Incidence of weight loss in head and neck cancer patients on commencing radiotherapy treatment at a regional oncology centre. Eur J Cancer Care (Engl) 1999;8:133–6.
   PubMed Web of Science ®Google Scholar
• Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, . Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009;20:1771–85.
   PubMed Web of Science ®Google Scholar